Literature DB >> 11799151

Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication.

Feng Li1, Chaoping Chen, Bridget A Puffer, Ronald C Montelaro.   

Abstract

We have previously demonstrated by Gag polyprotein budding assays that the Gag p9 protein of equine infectious anemia virus (EIAV) utilizes a unique YPDL motif as a late assembly domain (L domain) to facilitate release of the budding virus particle from the host cell plasma membrane (B. A. Puffer, L. J. Parent, J. W. Wills, and R. C. Montelaro, J. Virol. 71:6541-6546, 1997). To characterize in more detail the role of the YPDL L domain in the EIAV life cycle, we have examined the replication properties of a series of EIAV proviral mutants in which the parental YPDL L domain was replaced by a human immunodeficiency virus type 1 (HIV-1) PTAP or Rous sarcoma virus (RSV) PPPY L domain in the p9 protein or by proviruses in which the parental YPDL or HIV-1 PTAP L domain was inserted in the viral matrix protein. The replication properties of these L-domain variants were examined with respect to Gag protein expression and processing, virus particle production, and virus infectivity. The data from these experiments indicate that (i) the YPDL L domain of p9 is required for replication competence (assembly and infectivity) in equine cell cultures, including the natural target equine macrophages; (ii) all of the functions of the YPDL L domain in the EIAV life cycle can be replaced by replacement of the parental YPDL sequence in p9 with the PTAP L-domain segment of HIV-1 p6 or the PPPY L domain of RSV p2b; and (iii) the assembly, but not infectivity, functions of the EIAV proviral YPDL substitution mutants can be partially rescued by inclusions of YPDL and PTAP L-domain sequences in the C-terminal region of the EIAV MA protein. Taken together, these data demonstrate that the EIAV YPDL L domain mediates distinct functions in viral budding and infectivity and that the HIV-1 PTAP and RSV PPPY L domains can effectively facilitate these dual replication functions in the context of the p9 protein. In light of the fact that YPDL, PTAP, and PPPY domains evidently have distinct characteristic binding specificities, these observations may indicate different portals into common cellular processes that mediate EIAV budding and infectivity, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799151      PMCID: PMC135910          DOI: 10.1128/jvi.76.4.1569-1577.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  Recent advances and remaining problems in HIV assembly.

Authors:  L Garnier; J B Bowzard; J W Wills
Journal:  AIDS       Date:  1998       Impact factor: 4.177

Review 2.  HIV-1 gag proteins: diverse functions in the virus life cycle.

Authors:  E O Freed
Journal:  Virology       Date:  1998-11-10       Impact factor: 3.616

3.  A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release.

Authors:  J Yasuda; E Hunter
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses.

Authors:  B Yuan; S Campbell; E Bacharach; A Rein; S P Goff
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro.

Authors:  F Li; B A Puffer; R C Montelaro
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding.

Authors:  R N Harty; J Paragas; M Sudol; P Palese
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.

Authors:  U Schubert; D E Ott; E N Chertova; R Welker; U Tessmer; M F Princiotta; J R Bennink; H G Krausslich; J W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle.

Authors:  B Yuan; X Li; S P Goff
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

9.  Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus.

Authors:  M R Raabe; C J Issel; R C Montelaro
Journal:  J Virol Methods       Date:  1998-03       Impact factor: 2.014

10.  Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly.

Authors:  B A Puffer; S C Watkins; R C Montelaro
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  47 in total

1.  Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4.

Authors:  Jillian M Licata; Martha Simpson-Holley; Nathan T Wright; Ziying Han; Jason Paragas; Ronald N Harty
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding.

Authors:  Vincent Dussupt; Paola Sette; Nana F Bello; Melodi P Javid; Kunio Nagashima; Fadila Bouamr
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

3.  Budding capability of the influenza virus neuraminidase can be modulated by tetherin.

Authors:  Mark A Yondola; Fiona Fernandes; Alan Belicha-Villanueva; Melissa Uccelini; Qinshan Gao; Carol Carter; Peter Palese
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

4.  Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus.

Authors:  Anthony P Schmitt; George P Leser; Eiji Morita; Wesley I Sundquist; Robert A Lamb
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity.

Authors:  Annett Stange; Ingrid Mannigel; Katrin Peters; Martin Heinkelein; Nicole Stanke; Marc Cartellieri; Heinrich Göttlinger; Axel Rethwilm; Hanswalter Zentgraf; Dirk Lindemann
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  The functionally exchangeable L domains in RSV and HIV-1 Gag direct particle release through pathways linked by Tsg101.

Authors:  Gisselle Medina; Yongjun Zhang; Yi Tang; Eva Gottwein; Marcy L Vana; Fadila Bouamr; Jonathan Leis; Carol A Carter
Journal:  Traffic       Date:  2005-10       Impact factor: 6.215

7.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42.

Authors:  Eric Ka-Wai Hui; Subrata Barman; Dominic Ho-Ping Tang; Bryan France; Debi P Nayak
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  In vitro and in vivo replication of influenza A H1N1 WSN33 viruses with different M1 proteins.

Authors:  Zhiguang Ran; Ying Chen; Huigang Shen; Xiaoxiao Xiang; Qinfang Liu; Bhupinder Bawa; Wenbao Qi; Laihua Zhu; Alan Young; Juergen Richt; Wenjun Ma; Feng Li
Journal:  J Gen Virol       Date:  2012-12-19       Impact factor: 3.891

10.  Functional replacement of a retroviral late domain by ubiquitin fusion.

Authors:  Anjali Joshi; Utpal Munshi; Sherimay D Ablan; Kunio Nagashima; Eric O Freed
Journal:  Traffic       Date:  2008-08-09       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.